Index
Index

Acetylcholine activity, mood disorders and, 84
Action Plan for Women’s Health, 137-38
ADA. See Americans With Disabilities Act of 1990
Adoption studies, 105
Affective disorders. See Mood disorders
Agoraphobia, 12, 63, 109, 111
Agranulocytosis, clozapine and, 53, 93
Alcohol abuse or dependence. See Substance abuse or dependence
Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), 130, 138
American Psychiatric Association (APA), 46, 114, 152
Amish studies of mental disorder genetics, 108
Anafranil. See Clomipramine
Animal models of mental disorders, 134-36
Antianxiety agents, 12, 13, 64
Antidepressant medications, 9, 10
  classes, and generic and brand names, 58
  panic disorder and, 12, 13, 63-64
  side effects of, 58
  therapeutic response to, 58, 83
Antipsychotic medications, 7, 52-53, 58, 92
Anxiety
  animal models of, 135
  depression and, 55, 59
Anxiety disorders. See also Obsessive-compulsive disorder; Panic disorder
  comorbid substance abuse and, 57
  DSM-III-R and, 59
  genetics of, 11, 13, 108-9
APA. See American Psychiatric Association
Arkansas Blue Cross and Blue Shield v. Doe, 162
Behavioral therapy
  definition of, 59
  obsessive-compulsive disorder and, 11, 62
  panic disorder and, 64
Biochemistry, 72-74
  of mood disorders, 10, 82-85
  of obsessive-compulsive disorder, 11, 88
  of panic disorder, 13, 90-91
  of schizophrenia, 7, 77-79, 82
Biological factors, evidence of involvement in mental disorders, 13, 93-94, 101, 112
Biological research of mental disorders, impact of, 18-19, 21, 112-13, 156-63
Biological rhythms. See Circadian rhythms
Bipolar disorder. See also Depression; Mania
  age at onset of, 9, 56
  animal models of, 10, 135
  comorbid substance abuse and, 57
  cost of, 93
  course of, 9, 56
  genetics of, 10, 107-8
  kindling and sensitization hypothesis of, 10, 87
  medication for, 58-59. See also Lithium, Carbamazepine
  prevalence of, 3, 9, 35, 56
  psychotherapy and, 9, 59
  risk of, 113
  serotonin receptor, 84, 112
  symptoms of, 8-9, 53-54
  treatment of, 9, 58-59
Bleuler, Eugen, 50
Brain banks, 17-18, 138-40
Brain chemistry
  mood disorders and, 10, 82-85
  obsessive-compulsive disorder and, 11, 88-89
  panic disorder and, 13, 90-91
  schizophrenia and, 7, 77-78, 82
  study of, 72-74
Brain structure and function, 38-39, 74-77
  mood disorders and, 85-86
  obsessive-compulsive disorder and, 11, 89-90
  panic disorder and, 13, 91-92
  schizophrenia and, 7-8, 79-81, 82
Brain tissue for research, availability of, 17-18, 138-40
Carbamazepine, 9, 10, 59
Chlorpromazine, 92
Circadian rhythms, mood disorders and, 10, 87
Clinical research, 136-38, 140-41
Clomipramine, 11, 62
Clozapine, 53, 93
Cognitive therapy
  definition of, 59
  for depression, 59
  for panic disorder, 64
Comorbidity, 111
  bipolar disorder and, 57
  depression and, 55
  obsessive-compulsive disorder and, 11, 61-62
  panic disorder and, 12
Compulsions, 11, 60-61
  frequency by type, 12, 63
Computerized axial tomography (CAT), 76, 77, 79, 86
Congress
  interest in neuroscience research, 26, 27, 39
  policy issues and options, 21-31
Cost of mental disorders, 3-5, 16, 35-36
Courts, definition of mental disorders and, 45, 162
Creativity, mental disorders and, 56, 115
D/ART program. See DEPRESSION Awareness, Recognition and Treatment program
Decade of the Brain resolution, 5-6, 26, 37, 169
Delusions, 47, 50, 51
Depression
  animal models of, 135
  anxiety and, 59
heterogeneity of, 54-55
medications for, 58
obsessive-compulsive disorder and, 61
public education about, 27-31, 154-55
DEPRESSION Awareness, Recognition and Treatment program, 27-29, 154-55
Depression, major
age at onset of, 8, 56, 107
comorbid substance abuse and, 57
course of, 56
diagnosis of, 55
disability days from, 35
genetics of, 107-8
personal account of symptoms of, 9, 54
prevalence of, 3, 8, 35, 56
risk of, 113
suicide and, 8, 53
symptoms of, 8, 53
treatment of, 8
Developmental factors, schizophrenia and, 8, 81
Dexamethasone-suppression test (DST), 85
Diagnostic and Statistical Manual of Mental Disorders, 46-47
criteria for major depression, 55
criteria for mania, 55
criteria for obsessive-compulsive disorder, 62
criteria for panic disorder, 64
criteria for schizophrenia, 47
Discrimination against persons with mental disorders, 24, 153, 157, 161
Division of Basic Brain and Behavioral Sciences (DBBBS), 16, 126-27, 128, 129
Division of Clinical Research (DCR), 16, 127-29
Dopamine
depression and, 83
obsessive-compulsive disorder and, 89
receptors, 38, 75, 92, 112
schizophrenia and, 7, 77-78, 82
Drugs
action of, 74
development of, 92-93
spending for, 4, 36
treatment of bipolar disorder, 9
treatment of major depression, 8
treatment of obsessive-compulsive disorder, 11, 62, 89
treatment of panic disorder, 12, 63-64
treatment of schizophrenia, 7, 52-53
DSM. See Diagnostic and Statistical Manual of Mental Disorders
ECT. See Electroconvulsive therapy
Electroconvulsive therapy, major depression and, 8, 58
Electroencephalograph (EEG), 76, 77, 80
Employment status
mood disorders and, 56
schizophrenia and, 51
Epidemiologic Catchment Area (ECA) Program, 3, 4, 35, 36
Ethical issues surrounding neuroscience advances, 23-24, 26, 39
Eugenics and mental disorders, 25, 39, 104, 161
Family studies, 105
Federal Coordinating Council for Science, Engineering, and Technology, 131
Federal funding for mental disorders research, 5, 14-17, 21-23, 37, 39, 123-31
Federal information transfer, 30-31
Fetal abnormalities, lithium and, 59
Fluoxetine:
action of, 83, 93
sales of, 93
side effects of, 58, 93
Foundation funding for mental disorders research, 15, 132
Freud, Sigmund, 37
Galton, Francis, 25, 103, 104
Gamma-aminobutyric acid (GABA), 84
Genetic counseling for mental disorders, 113-15
Genetic heterogeneity, 109-10
Genetic information, privacy issues, 24, 39
Genetic mapping, mental disorders and, 109-12
Genetic research
impact of, 24, 112-13, 161
NIMH investment, 101
Genetics
anxiety disorders and, 108-9
basic concepts of, 101-3
mood disorders and, 10, 107-8
obsessive-compulsive disorder and, 11
panic disorder and, 13
schizophrenia and, 8, 106-7, 111
study and analysis of, 103-5
Hallucinations, 50, 51
Hand-washing compulsion, 11, 60
Homelessness, mental disorders and, 3, 35
Hormonal abnormalities and mood disorders, 10, 85
Hospitalization, 3, 4, 35, 36
costs of, 18, 23, 141
for major depression, 8, 58
for mania, 58
for schizophrenia, 52
Human Genome Project, 24, 39, 101
Imaging technology, 38, 71, 76-77
Immune and viral factors
mood disorders and, 88
obsessive-compulsive disorder and, 8, 81
Incarceration, mental disorders and, 3, 35
Information on mental disorders, 19, 20, 26-31, 153
Inheritance. See Genetics
Insurance coverage for mental disorders, 18-19, 161-63
Interagency Task Force on Hopelessness and Severe Mental Illness, 26, 153
Interpersonal psychotherapy, definition of, 59
James, William, 158
Kennedy, Edward M., 39
Kindling and sensitization hypothesis of bipolar disorder, 10, 87
Kraepelin, Emil, 45, 50
Legal issues surrounding neuroscience advances, 23-24, 26, 39
Linkage analysis, 105-6, 109-12
Lithium, 9, 10, 56, 58, 84-85, 93
LOD score, 106
LSD (lysergic acid diethylamide), 78
Magnetic resonance imaging (MRI), 76, 77, 79, 86
Major depression. See Depression, major
Mania. See also Bipolar disorder
animal models of, 135
course of, 56
diagnosis of, 55
medication for, 9, 58
Manic-depressive illness. See Bipolar disorder
MAOIs. See Monoamine oxidase inhibitors
Marital status
mood disorders and, 56
schizophrenia and, 50
Media portrayals of mental disorders, 20, 153, 159
Melancholia, 55
Mendel, Gregor, 101
Mental disorders. See also Anxiety disorders; Bipolar disorder
Depression, major; Mood disorders;
Obsessive-compulsive disorder; Panic disorder;
Schizophrenia
animal models of, 134-36
brain structure and function and, 74-77
classification of, 14, 109-12
comorbid substance abuse and, 57
cost of, 3-5, 16, 35-36
creativity and, 56, 115
definition of, 4546
eugenics and, 25, 104
evidence of biological factors involved in, 13, 93-94, 101
medical model of, 162
methods of study of, 71-77
prevalence of, 3, 35
risk of, 113
Mental health care, insurance coverage for, 18-19, 161-63
Mental health professionals, 45
suicide and, 6-7, 52
violence and, 20, 158, 159
Mental health services
cost of, 4, 36
government funding for, 5, 37
Microscopy, 38
Molecular biology, 38, 71, 74
Monoamine oxidase inhibitors
action of, 82
generic and brand names, 58
Mood disorders. See also Bipolar disorder; Depression, major
biochemistry of, 10, 82-85
brain structure and function and, 85-86
classification of, 54-55
comorbidity and, 56, 57
genetics of, 10, 107-8
hormonal abnormalities and, 10, 85
immune and viral factors, 88
prevalence of, 8-9, 56
social correlates of, 56
suicide and, 7, 52
symptoms of, 10, 53-55
treatment of, 8-9, 56, 58-59
National Advisory Mental Health Council, 39, 130
National Alliance for Research on Schizophrenia and Depression (NARSAD), 15, 132
National Alliance for the Mentally Ill (NAMI), 15, 37, 132, 154, 156, 160, 161
National Depressive and Manic Depressive Association, 132
National Institute of Mental Health (NIMH)
D/ART program, 27-29, 154-55
genetic counseling and, 114
genetic research investment, 101
mental disorder research funding, 14-17, 21-22, 123-29
neuroscience research and, 6, 21-22, 38, 123-30
research budget, 15, 17, 39, 124-25
National Institute on Aging, 124
National Institutes of Health (NIH), 130-31, 138
stigma attached to, 3, 5, 26, 151-53, 163
study of genetics of, 103-5, 113-16, 161
violence and, 20, 158, 159
Mental health care, insurance coverage for, 18-19, 161-63
Mental health professionals, 45
violence and, 20, 158, 159
Mental health services
cost of, 4, 36
government funding for, 5, 37
Microscopy, 38
Molecular biology, 38, 71, 74
Monoamine oxidase inhibitors
action of, 82
generic and brand names, 58
Mood disorders. See also Bipolar disorder; Depression, major
biochemistry of, 10, 82-85
brain structure and function and, 85-86
classification of, 54-55
comorbidity and, 56, 57
genetics of, 10, 107-8
hormonal abnormalities and, 10, 85
immune and viral factors, 88
prevalence of, 8-9, 56
social correlates of, 56
suicide and, 7, 52
symptoms of, 10, 53-55
treatment of, 8-9, 56, 58-59
National Advisory Mental Health Council, 39, 130
National Alliance for Research on Schizophrenia and Depression (NARSAD), 15, 132
National Alliance for the Mentally Ill (NAMI), 15, 37, 132, 154, 156, 160, 161
National Depressive and Manic Depressive Association, 132
National Institute of Mental Health (NIMH)
D/ART program, 27-29, 154-55
genetic counseling and, 114
genetic research investment, 101
mental disorder research funding, 14-17, 21-22, 123-29
neuroscience research and, 6, 21-22, 38, 123-30
research budget, 14-15, 17, 39, 124-25
National Institute on Aging, 124
National Institutes of Health (NIH), 130-31, 138
National Mental Health Association, 132
National Science Foundation (NSF), 133
Neuroendocrine systems, mood disorders and, 85
Neuropeptides, 38, 84
Neuroscience
  ethical, legal, and social issues, 23-24, 26, 39
  federal funding for research, 5, 21-23, 37, 39, 130-132
  growth and advances in field of, 5-6, 37-38, 156, 163
  research, 38-39
Neurotransmitters, 38
  action of, 72-74
  mood disorders and, 82-85
  schizophrenia and, 77-79
NIMH. See National Institute of Mental Health
Norepinephrine receptors, 84

Obsessions, 60-61
  frequency by type, 12, 63
Obsessive-compulsive disorder
  age at onset of, 11, 62
  animal models of, 135
  biochemistry of, 88-89
  brain structure and function and, 11, 89-90
  comorbidity and, 57, 61
  course of, 11, 62
  genetics of, 108-9
  individual experience of, 60-61
  manifestations of, 11, 60-61, 88
  prevalence of, 3, 11, 35, 62
  risk of, 113
  Tourette’s syndrome and, 11, 62, 89-90, 109, 111
  treatment for, 11, 62
OCD. See Obsessive-compulsive disorder

Panic disorder
  age at onset of, 12, 63
  brain chemistry of, 13, 90-91
  brain structure and function and, 13, 91-92
  comorbid substance abuse and, 57
  course of, 12, 63
  genetics of, 13, 108-9
  prevalence of, 3, 12, 35, 63
  risk of, 113
  suicide and, 7, 52
  symptoms of, 11-12, 62-63
  theories of origin of, 12-13, 90
  treatment of, 12, 63-64
Penfield, Wilder, 38
Personality disorders, schizophrenia and, 50, 106
Pharmacogenetics, 111
Phencyclidine (PCP), 79
Phenotype, 111
Phenylketonuria (PKU), 112
Positron emission tomography (PET), 74, 76, 77, 79, 80
postmortem brain tissue availability, 17-18, 138-40
Prescription drugs. See Drugs
President’s Commission on Mental Health, 5, 37
Productivity losses and mental disorders, 4, 35, 36
Prozac. See Fluoxetine
Psychodynamic psychotherapy, definition of, 59
Psychological tests, 38, 76
Psychopharmacology. See Drugs
Psychosis
  bipolar disorder and, 9
  major depression and, 53
  mania and, 54
  schizophrenia and, 6, 50
Psychosocial factors and mental disorders, 13, 71, 112, 161
Psychotherapy
  bipolar disorder and, 9, 59
  major depression and, 8, 58
  modalities of, 59
  obsessive-compulsive disorder and, 11, 62
  panic disorder and, 12, 63-64
  schizophrenia and, 52
Public attitudes toward mental disorders, 3, 5, 26, 151-56, 163
Public education about depression, 27-29, 154-55
Public Health Service (PHS) Guidelines for Animal Care and Use, 134-35
Reproductive hormonal alterations, mood disorders and, 10, 55, 85
Research into mental disorders
  animal models for, 134-36
  barriers to, 16-18
  brain tissue and, 17-18, 138-40
  clinical studies, 136-38, 140-41
  federal funding for, 5, 14-17, 21-23, 37, 39, 123-31
  impact of, 18-19, 21, 156-63
  public concern and, 14-16
Responsibility for mental disorders, perceptions of, 19-20, 156, 158, 160-61
Risk of mental disorders, 113
SAD. See Seasonal affective disorder
Schizoaffective disorder, 50, 108
Schizophrenia
  age at onset of, 8, 51
  animal models of, 135
  biochemistry of, 7, 77-79, 82
  brain structure and function and, 7-8, 79-81, 82
  comorbid substance abuse and, 57
  conceptualization of, 50
  course of, 8, 50-51
  developmental factors and, 8, 81
  DSM-III-R criteria for, 47
  genetics of, 8, 106-7, 111
  hypothesized causes of, 8, 50
  immune and viral factors, 8, 81
  individual experience of, 48-49, 158
  prevalence of, 3, 6, 35, 50-51
  risk of, 106, 113
smooth-pursuit eye movements and, 111-12
socioeconomic correlates of, 51
suicide and, 6-7, 52
symptoms of, 6-7, 47, 50, 51-52, 77
treatment of, 7, 52-53
“Schizophrenogenic” mother, 112, 160
Scottish Rite Foundation, 132
Seasonal affective disorder
characteristics of, 55, 87
treatment of, 8, 58
Serotonin
mood disorders and, 83
obsessive-compulsive disorder and, 11, 62, 88-89
receptors, 84, 112
suicide and, 83
Single-photon-emission computed tomography (SPECT), 76-77
Sleep disturbances, mood disorders and, 10, 86-87
Smooth-pursuit eye movements (SPEM) and schizophrenia, 111-12
Social issues surrounding neuroscience advances, 23-24, 26, 39
Society for Neuroscience, membership of, 5, 37
Socioeconomic status
mood disorders and, 56
schizophrenia and, 50, 56
State and local government funding for mental health services, 5, 37, 131-32
Sterilization, compulsory, and eugenics, 25, 104, 113
Stigma attached to mental disorders, 3, 5, 26, 151-53, 163
Styron, William, account of depression, 9, 54
Substance abuse or dependence, 3, 35
mental disorders and, 57
obsessive-compulsive disorder and, 11, 61-62
prevalence of, 57
Suicide
major depression and, 8, 53
mental disorders and, 6-7, 52
schizophrenia and, 7, 51-52
serotonin and, 83
Tardive dyskinesia, 53
Tourette’s syndrome and obsessive-compulsive disorder, 11, 62, 89-90, 109, 111
Tricyclic antidepressants
action of, 82
generic and brand names, 58
Twin studies, 105
U.S. Department of Agriculture, regulation of biomedical research on animals, 135
U.S. Department of Veterans Affairs
hospital care for persons with mental disorders, 3, 4, 36
mental disorders research by, 22-23, 130
Uniform Anatomical Gift Act of 1987, 140
VA. See U.S. Department of Veterans Affairs
Violence and mental disorders, 20, 158, 159
Viral factors
mood disorders and, 88
schizophrenia and, 8, 81